Cytolon AG is the first enabling technology company to fulfill the central needs of personalized medicine. Personalized medicine is based on matching the patient´s personal genomic and histocompatibility data with the characteristics of a given product in order to achieve the best possible therapeutic effect. Accurate and timely matching of patient and product is an absolute condition of personalized medicine with pharmaceutical companies needing to match and provide appropriate products to hundreds of thousands of patient cases at any time. A comprehensive solution can only be provided by intelligent internet-based matching platforms. As of today, there is no matching platform that fulfills these needs. Cytolon was created to fill this gap. Its corporate mission is to be the world’s first trusted source for obtaining the correct, best-matched personalized product in a timely and cost-effective manner. Cytolon will meet the requirements of personalized medicine through high performance matching, comprehensive logistics and appropriate data management for clinical development. 

Since allogeneic cord blood units and their inherent stem cells are the first existing personalized products in clinical practice, Cytolon is initially focusing on this market. An accurate, timely matching process is imperative as a cord blood unit (CBU) must perfectly match the histocompatibility antigens and genetic needs of the patient and must be delivered within days. Cytolon has developed a proprietary, patent-pending, global internet-based, high-performance cord blood brokering platform termed CordMatch^®. This platform is unique, as it integrates product search and matching, selection and logistics plus billing and follow-up.

Please read more about it or directly enter the CordMatch^® page.

Cytolon AG © 2010 – Matching the Power of Stem Cells | CordMatch^®